Celsee Diagnostics and collaborators publish validation study of automated CTC platform using clinical blood samples
Celsee Diagnostics, an innovator of cutting-edge products of liquid biopsy, announces the publication of “Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples” in PLOS ONE.
The peer-reviewed publication, developed in collaboration with The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Sidney Kimmel Cancer Center, Thomas Jefferson University and Comprehensive Cancer Center, University of Michigan, reveals that the Celsee microfluidic chip, used as part of the integrated Celsee system for automated staining and scanning provides a promising circulating tumor cells (CTC) platform.
The study demonstrated that the automated Celsee PREP400 system can readily capture and further characterize CTCs with molecular markers from clinical blood samples of patients with metastatic breast, prostate and colorectal cancer. The Celsee ANALYZER obtained high-definition images of immunostained CTCs in all 3 cancer types tested to date. Moreover, the system allows for downstream characterization of the captured cells by immunohistochemistry, DNA and mRNA fluorescence in-situ hybridization (FISH) on the microfluidic chip.
“There continues to be a need for simple, non-invasive and inexpensive tests for therapy choice and monitoring in oncology diagnostics. Improved enumeration and molecular characterization of CTCs may predict therapeutic response based on a single blood draw for routine clinical testing. Further development of the Celsee technology could potentially facilitate personalized treatment and improved patient outcomes,” stated Celsee Diagnostics’ Chief Scientific Officer Yixin Wang, Ph.D.
Read the full article in PLOS ONE.
About Celsee Diagnostics
Celsee Diagnostics, a privately-held Michigan-based company, develops automated systems for rare CTC enrichment and single-cell analysis. The company’s precise, accurate, and reliable platform for research and clinical diagnostics development will allow healthcare professionals more time to focus on their patients’ therapeutic treatment and outcomes. The label-free Celsee PREP platforms perform all the required processing steps to isolate and execute downstream single-cell analysis including immunochemistry, DNA FISH and mRNA FISH, while the Celsee ANALYZER scans and analyzes the prepared slide automatically. For more information, visit www.celsee.com.
About PLOS ONE
The world’s first multidisciplinary Open Access journal, PLOS ONE accepts scientifically rigorous research, regardless of novelty. PLOS ONE’s broad scope provides a platform to publish primary research, including interdisciplinary and replication studies as well as negative results. The journal’s publication criteria are based on high ethical standards and the rigor of the methodology and conclusions reported. For more information, visit www.plosone.org.